PCSK9 and familial hyperaldosteronism: ED as well as ASCVD may be considered as two different conditions of the same vascular burden and are related to LDL-C levels [36,37]; in this context, novel lipid lowering therapies such as PCSK9-i may be useful to reduce the double vascular burden of FH male patients.